SIGA Technologies

SIGA Technologies is a leader in global health focused on the development of innovative medicines to treat and prevent infectious diseases, primary orthopoxviruses. Through partnerships with governments and public health agencies, they work to build a healthier and safer world by providing essential countermeasures against these global health threats. It’s flagship product, TPOXX® (tecovirimat), is an antiviral medicine approved in the U.S. and Canada for the treatment of smallpox and authorized in Europe, the UK, and Japan for the treatment of smallpox, mpox, cowpox, and vaccinia complications.